Osteoclasts are highly differentiated multinucleated giant cells that play fundamental roles in bone resorption 26 and in the pathogenesis of osteolytic conditions, such as osteoporosis and cancer-induced bone loss.
Introduction

41
Osteoporosis is an increasingly prevalent bone disease predominantly affecting individuals over the age of 50, 42 which is characterized by reduced bone mineral density (BMD) and deterioration in bone microarchitecture 43 (Burge et al., 2007; Melton et al., 1992; Ray et al., 1997) . With an increasingly ageing population, the 44 prevention and treatment of osteoporotic diseases is becoming a significant economic and social burden on 45 society (Goldshtein et al., 2017) . Bone undergoes continuous remodeling throughout life, with osteoblasts 46 responsible for bone formation whilst osteoclasts regulate bone resorption (Saint-Pastou Terrier and Gasque, 47 2017; Vaananen, 2005) . The osteoclast, as the main functional cell of bone resorption, plays a vital role in the 48 loss of bone associated with the development of osteoporosis (Martin and Sims, 2005) . Osteolytic conditions 49 occur when the concerted processes of bone resorption and bone formation are dysfunctional, caused by 50 enhanced osteoclast formation and function, or reduced osteoblast formation and function (Kular et al., 2012;  51 Xu et al., 2009 ). Therefore, inhibition of osteoclastogenesis and osteoclast function is a major focus in the 52 treatment of osteoporosis and prevention of excessive bone loss.
54
Osteoclasts are specialized multinucleated cells derived from the monocyte/macrophage haematopoietic 55 lineage (Teitelbaum, 2000) . The formation of osteoclasts involves the interaction between receptor activator of 56 NF-κB ligand (RANKL), produced by osteoblast lineage cells, and RANK receptor, expressed in 57 pre-osteoclasts . The interaction between RANKL and RANK stimulates MAPK, 58 NF-κB and calcium signaling pathways in pre-osteoclasts (Negishi-Koga and Takayanagi, 2009).
59
Consequently, these pathways activate downstream osteoclastogenesis related transcription factors such as 60 NFATc1 and c-Fos (Wagner and Matsuo, 2003) . Previous studies in NFATc1 knockout mice have shown that 61 NFATc1 is essential for osteoclast differentiation and function (Aliprantis et al., 2008) . However, ectopically 62 expressed NFATc1 can effectively stimulate differentiation of pre-osteoclasts into mature osteoclasts.
63
Macrophage colony-stimulating factor (M-CSF) plays a critical role in the proliferation, differentiation and 64 activation of monocytes/macrophages (Kim and Kim, 2016) . M-CSF binds to the receptor c-FMS on 65 pre-osteoclasts and mature osteoclasts to regulate their survival and proliferation (Rosenfeld et al., 2015) . In (Figure 2A) . Consistent with the results of the osteoclast 193 formation assay, we found that both osteoclast number and the average number of nuclei per osteoclast were 194 decreased significantly by treatment with ABP at the concentrations of 6.5 and 10 μM (Figure 2B, 2C) .
195
Therefore, ABP has a dose-dependent inhibitory effect on RANKL-induced osteoclastogenesis.
197
ABP inhibits RANKL-induced osteoclastic hydroxyapatite resorption activity 198
To further evaluate the effect of ABP on osteoclast function, we performed a hydroxyapatite resorption assay 199 ( Figure 3A) . We found that the hydroxyapatite resorption area was significantly reduced in groups treated with 200 6.5 and 10 μM ABP when compared to groups treated with RANKL and M-CSF alone (Figure 3B, 3C) . These 201 data indicate that ABP can also attenuate the resorption activity of osteoclasts. (Figure 5B) . Expression of c-Fos, a 217 critical component of the transcription factor AP-1, was also suppressed in the presence of ABP on days 3 and 5 218 compared to control groups (Figure 5B) . Furthermore, following treatment with ABP, the expression of bone 219 resorption related proteins such as V-ATPase-d2, CTSK and Integrin-β3 was down regulated on days 3 and 5 220 ( Figure 5B) . 221 13 222
ABP suppresses MAPK pathways but has little effect on the NF-κB pathway during osteoclastogenesis 223
To investigate the regulation of RANKL-mediated MAPK and NF-κB pathways by ABP, western blot and 224 luciferase reporter assays were performed. We found that ABP at a concentration of 10 μM inhibited 225 phosphorylation of JNK1/2 at 60 min. In addition, groups treated with ABP showed significant decreases in 226 ERK1/2 and p38 phosphorylation at 10 and 20 minutes compared to control groups (Figure 6) . Furthermore, we 227 performed luciferase reporter assay to evaluate the effect of ABP on NF-κB activity. The results revealed that 228 ABP failed to alter NF-κB transcriptional activity (Figure S1A) . The western blot results were consistent with 229 luciferase reporter assay and showed that ABP had no effect on degradation of IκB-α (Figure S1B) 
